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Aim: To assess the influence of the treatment with 5-azacytidine (5-aza) on the profile of metal-containing proteins and factors 
of their regulation in Guerin carcinoma cells in vivo. Materials and Methods: The study was conducted on Wistar rats transplanted 
with wild-type Guerin carcinoma (Guerin/WT) and its strains resistant to cisplatin (Guerin/CP) or doxorubicin (Guerin/Dox). 
Animals were distributed in 6 groups treated with 5-aza and control animals without treatment. 5-Aza was injected by i.v. route 
(1 injection in 4 days at a dose of 2 mg/kg starting from the 4th day after tumor transplantation, 4 injections in total). Ferritin 
levels in blood serum and tumor tissue were measured by ELISA, transferrin and free iron complexes — by low-temperature EPR, 
miRNA-200b, -133a and -320a levels and promoter methylation — by real-time quantitative reverse transcription polymerase chain 
reaction. Results: The study has shown that 5-aza treatment caused demethylation of promoter regions of fth1 and tfr1 genes in all 
studied Guerin carcinoma strains. 5-Aza treatment resulted in a significant decrease of ferritin levels in tumor tissue (by 32.1% 
in Guerin/WT strain, by 29.8% in Guerin/Dox and by 69.1% in Guerin/CP). These events were accompanied by 3.5-fold and 
2-fold increase of free iron complexes levels in tumor tissue of doxorubicin and cisplatin resistant strains, respectively. Also, 5-aza 
treatment resulted in significantly elevated levels of miR-200b, -133a, 320a expression in tumor tissue. After 5-aza treatment, 
ferritin levels in blood serum of animals with Guerin/Dox were increased by 23.9%, while in Guerin/Wt and Guerin/CP they were 
decreased by 17 and 16%, respectively. Conclusion: Alterations of epigenetic regulation upon in vivo treatment with 5-aza change 
the levels of metal-containing proteins due to DNA demethylation and altered miRNA expression profiles in Guerin carcinoma cells.
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�espite recent advances in understanding tumor 
nature� many questions remain unanswered. One 
of them is the possi�ility of exogenous correction 
of certain tumor features. Solving this pro�lem would 
give us radically new approaches in cancer therapy� 
which would make tumors more sensitive to cytostatic 
drugs and allow to decrease toxic side effects [�].
One of the most promising targets� which could 
significantly affect tumor features� is iron meta�olism 
�ecause this element is a vital cofactor for many im-
portant cellular processes �energy synthesis� transcrip-
tion� cell division� oxidation reactions etc.� [�]. �uring 
last few years it has �een shown that many features 
of cancer cells in vitro and tumors in vivo are associ-
ated with different aspects of iron meta�olism. In our 
previous works we already descri�ed the changes 
in this process� in particular� altered expression of dif-
ferent metal-containing proteins in tumor cells with 
different degree of malignancy and different sensitivity 
to cisplatin and doxoru�icin [�]. Also� we revealed that 
Walker-�5� carcinosarcoma showed gradual changes 
in the levels of different metal-containing proteins at dif-
ferent stages of the development of resistance to doxo-
ru�icin. Those changes were o�served �oth in tumor 
tissue and in �lood serum of the host organism [4].
Another pro�lem is the search for useful mecha-
nisms to correct mentioned changes in iron meta�o-
lism and the levels of metal-containing proteins [5]. 
One of the promising approaches is related to epigene-
tic mechanisms of regulation of protein expression� 
such as changes in �NA methylation patterns and 
miRNA expression profiles [�].
In �9�4 Czechoslovakian scientists synthesized 
5-aza-�'deoxycytidine �5-azacytidine� which was 
a new potential chemotherapeutic drug [�]. Later 
other scientists discovered that mechanisms of cyto-
toxic action of high dose 5-azacytidine �5-aza� were 
�ased on its incorporation into �NA and RNA� result-
ing in �reaks in nucleic acid chains and cell apopto-
sis� while low doses of this compound inhi�ited �NA 
methyltransferase activity and caused �NA hypo-
methylation. This demethylation activity could result 
in altered profile of metal-containing proteins and 
changed tumor phenotype [�].
So� the aim of our study was to assess the influence 
of the treatment with 5-aza on the profile of metal-
containing proteins and factors of their regulation 
in Guerin carcinoma cells in vivo.
MATERIALS AND METHODS
Experimental animals. Studies were carried 
out on �� Wistar female rats with su�cutaneously 
transplanted Guerin carcinoma strains� wild type �WT� 
or resistant to cisplatin �Guerin/CP� and doxoru�icin 
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Abbreviations used: 5-aza — 5-azacytidine; CP — cisplatin; Dox — 
doxorubicin; EPR — electron-paramagnetic resonance; FTH — fer-
ritin heavy chains; MSP — methylation-specific PCR; PCR — poly-
merase chain reaction; qRT-PCR — real-time quantitative reverse 
transcription PCR; TFR — transferrin receptor.
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(Guerin/Dox) (2•10� cells per animal�. These tumor 
strains were o�tained from National Bank of Cell Lines 
and Transplanted Tumors of R.E. Kavetsky Institute 
of Experimental Pathology� Oncology and Radio�io-
logy� National Academy of Sciences of Ukraine �Kyiv� 
Ukraine�. The use and care of the experimental animals 
have �een performed in accordance with the standard 
international rules of �iologic ethics and was approved 
�y Institutional Animal Care and Use Committee.
Animals were distri�uted in � groups ��� animals 
per group�: �� Guerin/WT� control; �� Guerin/WT treated 
with 5-aza; �� Guerin/CP� control; 4� Guerin/CP treated 
with 5-aza; 5� Guerin/�ox� control; 4� Guerin/�ox 
treated with 5-aza.
�� animals from each group received 5-aza �Gede-
on-Richter� Czech Repu�lic� treatment: � injection 
each 4 days i/v at a dose of � mg/kg starting from the 
4th day after tumor transplantation� 4 injections in total. 
All of the studied parameters were measured on the 
��th day after tumor transplantation.
ELISA. Ferritin levels in �lood serum and tumor 
tissue were measured �y automatic �iochemical and 
immunoenzyme analyzer Chem Well �9�� �USA� us-
ing ferritin ELISA kit �Uscer� China� according to the 
instruction of the manufacturer. Blood serum samples 
were collected and tumor homogenate was prepared 
and stored at −�� °C.
Low-temperature electron-paramagnetic 
resonance (EPR). Transferrin levels in �lood serum 
and tumor tissue were measured using EPR method 
using computerized spectrometer R-���� �Russia� 
at �� К� E�TA sodium salt was used as anticoagulant. 
Stripe width was �5�5 G� frequency — 9.�5 GHz� 
microwave power — 4� mW� amplitude modulation — 
��.� G� frequency modulation — ��� kHz. g-Factor 
was calculated using standard formula:
g = hν/βH,
where h is Plank’s constant� ν — frequency� 
β — Bohr’s magneton� H — external magnetic field 
in resonance.
Apoptosis and necrosis rates were estimated 
using classical Annexin V/PI method as previously 
descri�ed [5] with the use of BeckmanCoulter EPICS® 
XL Flow cytofluorimeter.
Total DNA isolation. Total �NA extraction was 
performed with “�NA-Sor� B” �NA Isolation Kit �Am-
plisens� Russia� according to the manual� provided 
�y manufacturer.
Methylation-specific polymerase chain reac-
tion (PCR) (MSP). Bisulfite conversion involves the 
deamination of unmodified cytosine residues to uracil 
under the influence of hydrosulfite ion from water solu-
tion of sodium �isulfite. Such treatment doesn’t affect 
5-mC and in further amplification uracils are amplified 
as thymines� whereas 5-mC residues get amplified 
as cytosines. Bisulfite conversion was performed 
using EZ �NA Methylation Gold-Kit �Zymo Research� 
USA� according to manufacturer’s protocol. Aliquots 
of �isulfite-modified �NA were stored at −�� ˚C and 
were used for MSP. MSP was performed using the 
standard protocols; primer sequences are availa�le 
in Ta�le �. TSH�B and GAP�H were used as reference 
control genes [9].
Table 1. Primer sequences, used in MSP
Gene Primer sequence Size of resulting product
FTH1_M F: 5' — cga ggg ttt tta gcg gtc — 3' 128 bpR: 5' — atc tct tat aac cgc gtc gac — 3'
FTH1_U F: 5' — gtg agg gtt ttt agt ggtt — 3' 128 bpR: 5' — aat ctc tta taa cca cat caa c — 3'
TFR1_M F: 5' — gta gtt ggg att ata ggc gc — 3' 180 bpR: 5' — taa tta cca aac gcg ata act c-3'
TFR1_U F: 5' — tga gta gtt ggg att ata ggt gt — 3' 180 bpR: 5' — taa tta cca aac aca ata act cac — 3' 
Notes: FTH1_M — ferritin heavy chains, methylated promoter; FTH1_U — 
ferritin heavy chains, unmethylated promoter; TFR1_M — transferrin re-
ceptor 1, methylated promoter; TFR1_U — transferrin receptor 1, unmethy-
lated promoter.
PCR products were analyzed �y agarose gel elec-
trophoresis in �.�% agarose “Low EEO� Type �-A” 
�Sigma� USA�. After electrophoresis the results was 
visualized �y ethidium �romide� photographed under 
UV light and evaluated �y a computer program Total-
La� v�.��.
Total RNA isolation. Total RNA extraction was 
performed with “Ri�ozol” RNA Isolation Kit �Ampli-
sens� Russia�. RNA concentration was measured 
with Nano�rop ����c Spectrophotometer �Thermo 
Scientific� USA�. Purity of isolated RNA was controlled 
�y analyzing the ratio of O� at ���/��� nm. RNA was 
dissolved in TE �uffer and stored at −�� °С.
Single-stranded c�NA was synthesized from 
��� ng of total RNA� using TaqMan® MicroRNA Kit for 
reverse transcription.
Real-time quantitative reverse transcription 
PCR (qRT-PCR). Reaction mix for reverse transcrip-
tion was prepared according to manufacturer’s proto-
col. Reverse transcription was performed with thermal 
cycler “Tertsik” �“�NA Tehnologіya”� Russian Federa-
tion�. qRT-PCR was performed on Applied Biosystems 
�9��HT Fast Real-Time PCR System using TaqMan® 
MicroRNA primers and manufacturer’s protocol.
Small nucleolar RNA RNU4� was used as an en-
dogenous control for normalization of miRNA expres-
sion. Relative expression of the studied miRNAs was 
identified �y comparative Ct method [�]. Experiments 
were performed in triplicates for each line� and PCR 
was performed three times for each sample. Expres-
sion differences �etween the studied miRNA levels 
relative to control was calculated �y the formula:
Fold change = 2−ΔΔCt [8],
where ΔCt �target — control� is equal to the diffe-
rence �etween threshold cycles for miRNA �target� and 
the threshold cycle for RNU4� �control�:
ΔCt (target — control) = Ct (target) — Ct(control);
ΔΔCt = ΔCt (experiment) − ΔCt (control).
Statistical analysis. Experimental data were ana-
lyzed using the Student’s t-test. p-Values less than 
�.�5 were considered statistically significant. Statisti-
cal analysis of the o�tained data was performed using 
the STATISTICA �.� software.
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RESULTS AND DISCUSSION
It is known that demethylating agents� such 
as 5-aza� enhance the expression of oncosuppressive 
genes [��]. In addition to affecting methylation status 
of promoter CpG islands� 5-aza targets are transcrip-
tion factors that are involved in the cell cycle regula-
tion. In particular� c-Myc activates expression of the 
transferrin receptor � �TfR��� ferritin and iron-regulated 
protein � �IRP��. These proteins are important regula-
tors of iron meta�olism in the cell� and are critical for 
proliferation and division of tumor cells [��].
We� resources �https://www.e�i.ac.uk/Tools/ 
seqstats/em�oss_cpgplot and https://genome. 
ucsc.edu� were used to analyze �NA segments 
at a distance of �.5 k� in up- and downstream regions 
from the transcription start sites. We found regula-
tory CpG-islands in promoter regions of transferrin 
receptor � �tfr1� and ferritin heavy chains �fth1� genes� 
as well as miRNA-���a� -����� and -���a.
Thus� we decided to investigate the changes 
in methylation status of CpG-islands in tfr1 and 
fth1 gene promoter areas in Guerin carcinoma strains� 
wild-type and resistant to doxoru�icin and cisplatin� af-
ter the session of 5-aza-�ased therapy. We esta�lished 
that the development of resistance to doxoru�icin and 
cisplatin is accompanied �y hypomethylation of stu-
died CpG areas �Ta�le ��. After 5-aza treatment� levels 
of the fth1 and tfr1 promoter methylation in all strains 
were almost identical pointing on their demethylation. 
The level of promoter methylation of transferrin recep-
tor � gene in the sensitive and resistant to doxoru�icin 
strains after 5-aza treatment were identical� while 
in cisplatin-resistant strain it was two times higher 
�see Ta�le ��.
However� the level of ferritin protein in the tumor 
tissue under the influence of 5-aza was reduced 
in all strains �Fig. ��� indicating that additional regula-
tory mechanisms are involved in response to genome 
methylation changes.
Another epigenetic mechanism� responsi�le for 
protein expression regulation is RNA interference� 
in which miRNAs play the major role. miRNAs are 
small noncoding RNAs� which regulate the expression 
of proteins at post-transcriptional level. For example� 
the targets of oncosuppressor miRNA-���� and -���a 
are mRNA of heavy �FTH�� and light �FTL� chains of fer-
ritin molecule. Together with CpG methylation of these 
genes� miRNA-���� and -���a regulate the presence 
of ferritin in the cells [��].
It was recently shown �on heme �inding protein 
�GCR�� that the changes in iron �alance in cells play 
a key role in the maturation of different miRNAs [��]. 
Iron-�ound transferrin �inds to transferrin recep-
tors � and � �TfR�� �� on a cell surface and enters the 
cell via endocytosis. Then divalent metal transpor-
ter � ��MT�� releases the iron into the cytoplasm� 
forming the “la�ile iron pool”� which can �e stored 
in ferritin or used �y mitochondria to synthesize heme. 
Heme is critical for the maturation of pre-miRNA tran-
scripts �ecause it �inds to the processing complex� 
which consists of �GCR� and �rosha proteins. An-
other way of iron-dependent regulation is pre-miRNAs 
export from the nucleus to the cytoplasm� where� 
Table 2. Changes of fth1 and tfr1 promoter methylation levels in Guerin carcinoma cells after 5-aza treatment
Genes
Level of promoter methylation (r. u.)
Guerin/WT Guerin/Dox Guerin/CP
Control + 5-aza Control + 5-aza Control + 5-aza
fth1 7.15 ± 0.24 2.40 ± 0.31* 4.50 ± 0.20# 2.30 ± 0.10*# 5.34 ± 0.30# 2.70 ± 0.60*#
tfr1 1.63 ± 0.01 1.27 ± 0.02* 2.25 ± 0.18# 1.21 ± 0.12*# 3.50 ± 0.10# 2.60 ± 0.11*#
Note: *p < 0.05 compared with control group; #p < 0.05 compared with control WT strain.
Table 3. Changes in expression of miRNA-133a, -200b and -320a in Guerin carcinoma tumor tissue after 5-aza treatment
ΔCt
Guerin carcinoma strain
WT Guerin/Dox Guerin/CP
Control + 5-aza Control + 5-aza Control + 5-aza
miR-133a 0.81 ± 0.01 1.72 ± 0.02* 0.41 ± 0.02# 1.33 ± 0.01*# 0.62 ± 0.01# 1.32 ± 0.01*#
miR-200b 0.70 ± 1.25 4.60 ± 0.61* 0.42 ± 0.05# 0.60 ± 0.01* 0.35 ± 0.25# 9.70 ± 0.15*#
miR-320a 0.29 ± 0.19 0.46 ± 0.08* 0.05 ± 0.04# 0.35 ±0.03* 0.11 ± 0.03# 0.39 ± 0.01*
Note: *p < 0.05 compared with control group; #p < 0.05 compared with control WT strain.
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Fig. 1. Changes of ferritin levels in tumor tissue of Guerin carci-
noma sensitive and resistant to cytostatics after 5-aza treatment. 
*p < �.�5 compared with control group; #p < �.�5 compared with 
control WT strain
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Fig. 2. Levels of free iron complexes in Guerin carcinoma tissue 
after 5-aza treatment. *p < �.�5 compared with control group; 
#p < �.�5 compared with control WT strain
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depending on iron levels� C-domain-�inding protein 
PCBP� forms active dimers. �imerized PCBP� �inds 
�ICER resulting in miRNA maturation. Increase of iron 
levels in a cell leads to PCBP� monomerization and its 
transition into inactive form [�4].
Measurement of free iron complexes �y EPR 
spectroscopy �Fig. �� showed that 5-aza treatment 
caused no changes in Guerin/WT cells. On the other 
hand� levels of free iron complexes in �oth resistant 
strains significantly elevated after 5-aza treatment and 
�ecame close to those of the sensitive strain.
Next� we have studied the effects of 5-aza on the 
levels of miRNA� which regulate different metal-con-
taining proteins. We found that 5-aza treatment caused 
the changes in the levels of miRNA-���a� -���� and 
���a in tumor cells of all studied Guerin carcinoma 
strains. Changes of the expression in miR-���a after 
demethylating agent exposition had unidirectional 
nature in sensitive and resistant Guerin carcinoma 
cells �Ta�le ��.
We determined that 5-aza treatment resulted in the 
increase of miR-���a and -���a levels in all three 
strains. Levels of miR-���� also increased in all stu-
died strains� �ut were the most pronounced in Guerin/
CP cells. O�tained data on miRNA-���a and -���� 
expression were in good accordance with the data 
on ferritin levels in tumor tissue� mentioned a�ove. So� 
despite hypomethylation of its promoter� fth1 expres-
sion is silenced �y miRNAs on the post-transctriptional 
level.
It is known that tfr1 and mdr1 mRNAs are direct 
targets of miRNA-���a. Overexpression of �oth pro-
teins is o�served in many cancer cells� resistant to dif-
ferent cytostatics. So� we speculate that the increase 
of microRNA-���a expression caused �y 5-aza� could 
sensitize malignant cells to anticancer drugs [�5].
�ue to constant �inding of �NMT enzymes� 5-aza 
causes apoptotic effect on poorly differentiated stem 
cells� �ut the exact mechanism of this influence is still 
unclear [��]. We assessed the apoptotic and necrotic 
rates of Guerin carcinoma cells� and it was found that 
in Guerin/WT the treatment with 5-aza resulted in the 
increased num�er of cells in a state of necrosis and 
apoptosis — �y ��.� and 49%� respectively� com-
pared to untreated control. In Guerin/CP and Guerin/
�ox cells under the influence of 5-aza� the num�er 
of cells in a state of necrosis did not change� and the 
num�er of cells in a state of apoptosis increased twice 
�Ta�le 4�.
So� we can conclude that 5-aza treatment resulted 
in unidirectional changes in all studied Guerin carcino-
ma strains. Particularly� we o�served hypomethylation 
of fth1 and tfr1 promoters� and� as a result� elevation 
of free iron levels in tumor cells. This caused significant 
increase of expression of miRNAs involved in regu-
lation of iron levels� resulting in silencing of ferritin 
expression and the loss of resistance to cytostatics.
These changes in tumor �ehavior were confirmed 
on organism level. After 5-aza treatment� in �lood 
serum of animals with Guerin/�ox ferritin levels were 
increased �y ��.9%� while in Guerin/WT and Guerin/
CP — decreased �y �� and ��%� respectively. Also� 
after 5-aza treatment we o�served lowering of ceru-
loplasmin activity �see Ta�le 4�. These results indicate 
that organism’s iron stores are depleted �in accor-
dance with the data on increase of free iron in tumor 
tissue�. �ecrease of ceruloplasmin activity in �lood 
serum �as we showed in our previous studies� is a non-
tumor marker of tumor sensitivity to chemotherapy.
So� we can conclude that of 5-aza can �e used 
as an exogenous modifier of the content of metal-
containing proteins �oth in tumor and in an organism. 
Moreover� 5-aza was capa�le to change some features 
of drug-resistant tumors� making them more sensi-
tive to cytostatics �ecause of mdr1 deregulation and 
decrease of ceruloplasmin activity in �lood serum.
Our results demonstrated that 5-aza could �e con-
sidered as a promising agent� which can �e used in low 
doses in com�ination with convenient chemotherapy 
�especially cisplatin and doxoru�icin� to increase 
antitumor effects.
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